CompletedPhase 2

Docosahexaenoic Acid (DHA) Supplementation During Pregnancy Reduces the Risk of Preterm Birth in Threatened Preterm Labor

Thailand60 participantsStarted 2024-04-01

Plain-language summary

The goal of this clinical trial is to learn about the effects of Docosahexaenoic acid (DHA) in reducing the incidence of premature birth in threatened preterm labor The main questions it aims to answer are: * Can DHA supplementation reduce the incidence of premature birth in threatened preterm labor? * How does DHA supplementation affect pregnancy outcomes? Participants were organized into two groups * Group 1 (Intervention) Participants will be asked to take a DHA 1000mg per day * Group 2 (control) Participant will not need to take a DHA

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Singleton pregnancy * Between 24 wk to 34 wk of gestational age * Pregnant women diagnosed threatened preterm labor (with no cervical change) Exclusion Criteria: * Fetal anomalies * Multiple pregnancy * Premature rupture of membrane * Placental disorders: placenta previa, placental abruption * Fetal growth restriction * Pregnancy complication: gestational diabetes mellitus, Chronic hypertension * Allergic reaction to DHA

What they're measuring

Number of Participants with preterm birth

Timeframe: at delivery time

Trial details

NCT IDNCT06302023

SponsorKhon Kaen University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-10-07

View on ClinicalTrials.gov More Pregnant Women Diagnosed With Threatened Preterm Labor trials